Stock 1877 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Delayed Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 am EDT 		5-day change 1st Jan Change
11.76 HKD +8.49% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. +26.59% -39.51%
Apr. 29 Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
MT
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
GL
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
CI
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes
CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection
MT
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
GL
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA
MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection
CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.
CI
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
GL
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates
MT
Junshi Bio's 2023 Loss Widens, Misses Estimates
MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Junshi Biosciences Proposes Share Buyback
MT
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
GL
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA
MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. News Shanghai Junshi Biosciences Co., Ltd.